New Weight-Loss drug HS235 begins first human tests
NCT ID NCT06714825
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested HS235, an experimental drug, in 39 overweight or obese but otherwise healthy adults. The main goal was to check safety and how the drug behaves in the body, not to measure weight loss. Participants received either HS235 or a placebo as a shot under the skin. Results will help decide if further studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HS235
What this could lead to
If safe and effective, HS235 could become a new option for weight management in people with overweight or obesity.
What could go wrong
This is a very early Phase 1 trial with only 39 people. It is designed to check safety and how the drug moves through the body, not whether it works for weight loss. Many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Syneos Clinical Research Unit
Québec, Quebec, Canada